WO2001027098A2 - Procede de preparation d'inhibiteurs cox-2 - Google Patents
Procede de preparation d'inhibiteurs cox-2 Download PDFInfo
- Publication number
- WO2001027098A2 WO2001027098A2 PCT/FR2000/002770 FR0002770W WO0127098A2 WO 2001027098 A2 WO2001027098 A2 WO 2001027098A2 FR 0002770 W FR0002770 W FR 0002770W WO 0127098 A2 WO0127098 A2 WO 0127098A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- general formula
- reaction
- alkyl
- chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC1(*)OC1(c(cc1)ccc1S(C)(=O)=O)O* Chemical compound CC1(*)OC1(c(cc1)ccc1S(C)(=O)=O)O* 0.000 description 2
- UDQYORBCPYJTRU-UHFFFAOYSA-N CC(C)(C(c1ccc(C)cc1)=O)OC(COCC1CC1)=O Chemical compound CC(C)(C(c1ccc(C)cc1)=O)OC(COCC1CC1)=O UDQYORBCPYJTRU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
Definitions
- the invention relates to a process for the preparation of (4-alkylsulfonyl) -phenyl-2- (5H) -furanones, which are compounds which inhibit cyclooxygenase-2 (COX-2); as well as new intermediate compounds useful for the preparation of these compounds.
- the second step of this process consists in brominating 4-thiomethyl-isobutyrophenone to obtain 4-thiomethyl- ⁇ -bromoisobutyrophenone.
- 4-thiomethyl- ⁇ -bromoisobutyrophenone is oxidized to 4-methylsulfonyl- -bromoisobutyrophenone which is a highly allergenic compound, this compound is then esterified with a carboxylic acid to form a 2-methyl-1 ester ( 4'-methylsulfonylphenyl) -1- oxo-prop-2-yl.
- This reaction is also accompanied by a certain number of by-products, among which an elimination product, 4- (4'-methyl-sulfonylphenyl) -2-methyl-propene.
- the aim of the invention is to propose an alternative to the process described in WO 97/45420 and in particular a general process for the preparation of substituted (4-alkylsulfonylphenyl) -2- (5H) -furanones compounds avoiding the problem posed by the intermediary of the ⁇ -bromoisobutyrophenone type, which is easy to use, avoids the formation of the disposal by-product and provides an acceptable final product yield.
- R 5 represents a group chosen from (1) a CC 6 linear branched or cyclic alkyl group;
- R 2 represents a (CC 6 ) alkyl group
- R 3 and R 4 independently of one another represent a hydrogen atom or a group CHR 6 R7 in which R 6 and R 7 are independently of one another chosen from:
- R ⁇ is chosen from:
- R 8 groups form together with the nitrogen atom to which they are attached a ring having 5 to 7 atoms, and optionally comprising a heteroatom chosen from O, S or NR 9 ;
- R 9 and Rio are independently of each other chosen from:
- R 2 , R 3 and R are as defined above and R- I2 represents a C 1 -C 6 alkyl group, with an acid of general formula
- step a) takes place in an anhydrous solvent, preferably an ether, for example diethyl ether, or methyltertiobutylether.
- the reaction temperature is advantageously between -20 and 40 ° C.
- step a) a compound of general formula IV is obtained as well as secondary products in minor quantities.
- the abovementioned elimination product does not form.
- the strong base is advantageously chosen from 1, 8-diazabicyclo [5.4.0] undec -7-ene (DBU), 1, 4-diazabicyclo [2.2.2] octane ( DABCO) and 1,5-diazabicyclo [4.3.0] non-5-ene (DBN).
- DBU 1, 8-diazabicyclo [5.4.0] undec -7-ene
- DABCO 4-diazabicyclo [2.2.2] octane
- DBN 1,5-diazabicyclo [4.3.0] non-5-ene
- the dehydrating agent can be chosen in particular from esters of trifluoroacetic acids, for example isopropyl trifluoroacetate, esters of trichloracetic acids and esters of alkyl or arylsulfonic acids.
- the reaction preferably takes place in an aprotic solvent such as acetonitrile, N, N-dimethylformamide, N-methylsulfoxide, propionitrile and nitromethane.
- an aprotic solvent such as acetonitrile, N, N-dimethylformamide, N-methylsulfoxide, propionitrile and nitromethane.
- the molar ratio of the ester of formula IV to the strong base is generally between 1: 1 and 1: 2, a ratio of 1: 1, 5 being preferred.
- the molar ratio of the cyclic ester of formula V to the dehydrating agent is generally from 1: 1 to 1: 2, a ratio of 1: 1, 2 being preferred.
- the reaction is carried out at a temperature preferably between 0 ° C and the reflux temperature of the solvent.
- Step c) is carried out in a manner known per se, in particular by elimination of the solvent, precipitation of the product, recrystallization, etc.
- the epoxy compound of general formula II can be obtained by reaction of a compound of general formula VI: previously, with an oxidizing agent. Mention may in particular be made, as oxidizing agent, of organic peracids, such as meta-chloroperbenzoic acid and peracetic acid or dioxiranes such as dimethyldioxirane, whether or not generated in situ.
- the reaction temperature is advantageously between -40 ° C and 30 ° C.
- the oxidizing agent is used in excess relative to the compound of general formula I I (3 to 40 equivalents), so as to oxidize on the one hand the olefinic function to epoxide, on the other hand the sulfide function to sulfone.
- the compound of general formula VI can be obtained by reaction of a compound of general formula VII:
- R12 being as defined above, in the presence of a catalytic amount of acid and a dehydrating agent.
- the acid is chosen from sulfonic acids, for example p-toluene sulfonic acid or mineral acids, for example hydrochloric acid.
- sulfonic acids for example p-toluene sulfonic acid or mineral acids, for example hydrochloric acid.
- dehydrating agent CC 6 alkyl orthoformates are preferred.
- reaction is carried out in an excess of alcohol of general formula VIII, the latter serving as reactive solvent.
- R 2 is advantageously a methyl group, the alcohol being methanol.
- the subject of the invention is also a process for the preparation of a compound of general formula I as defined above, characterized in that it comprises the following steps:
- X is a leaving group, preferably a chlorine atom to form a compound of general formula VII:
- R 12 represents a (C ⁇ -C 6 ) alkyl group to form a compound of general formula VI:
- R 2 , R 3 , R and R12 are as defined above;
- the Lewis acid is advantageously chosen from AICI 3 , FeCI 3 , TiCI and SnCI 4 without however being limited to these.
- Non-reactive solvents include halogenated and polyhalogenated hydrocarbons such as mono- or dihalo (C -C 4 ) alkyls, for example dichloromethane; aromatic solvents such as nitrobenzene or halogenated aromatic compounds, as well as branched or cyclic linear hydrocarbons in C ⁇ -Cio comprising in particular hexane, cyclohexane, methylcyclohexane or CS 2 .
- halogenated and polyhalogenated hydrocarbons such as mono- or dihalo (C -C 4 ) alkyls, for example dichloromethane
- aromatic solvents such as nitrobenzene or halogenated aromatic compounds, as well as branched or cyclic linear hydrocarbons in C ⁇ -Cio comprising in particular hexane, cyclohexane,
- the molar ratio of the compound of general formula IX to the compound of general formula X is generally between 1: 1.5 and 1.5: 1, with a ratio of 1: 1 to 1: 1.5 being preferred.
- the reaction is usually carried out with an excess of the compound of general formula X.
- the molar ratio of the compound of general formula IX to Lewis acid is between 1: 1.5 and 1.5: 1.
- the molar ratio of the compound of general formula IX to the Lewis acid is between 1: 1 and 1: 1.5.
- the reaction can advantageously be carried out in a temperature range between 0 and 25 ° C, preferably 5 and 15 ° C.
- the reactants are reacted until the reaction is complete, which occurs after an interval of 8 to 4 hours, usually 1 to 2 hours.
- the reaction is preferably carried out under a nitrogen atmosphere. Steps (2) to (6) are carried out under conditions as described above.
- the compounds of general formula IX and X are compounds which are commercially available or which can be easily prepared by a person skilled in the art by implementing well-known routine methods.
- Ri is a group RO, R being as defined above for R 5 .
- the process according to the invention comprises in this case the following steps: a) reaction of a compound of general formula II
- R 2 , R 3 and R 4 are as defined above and R 12 represents a C ⁇ -C 6 alkyl group, with an acid of general formula IIIa
- R 2 is as defined above and X is chosen from:
- the process of the invention then comprises the following stages a) reaction of a compound of general formula I I
- R 2 , R 3 and R 4 are as defined above and R 12 represents a CC 6 alkyl group, with an acid of general formula III b)
- the intermediate compound of general formula VI is new and constitutes another object of the invention.
- a particularly preferred compound of this type is that in which R ⁇ 2 represents methyl.
- reaction mass is then heated 41 h at 115 ° C. After returning to ambient temperature, the reaction mixture is diluted with dichloromethane (50 ml), washed with a saturated aqueous solution of potassium carbonate (50 ml) then with brine (50 ml) and dried over sodium sulfate. Evaporation of the solvents provides a mixture of expected 1-methoxy-2-methyl-1- (4'-methylthiophenyl) prop-1-ene and 1, 1-dimethoxy-2-methyl-1- (4'-methylthiophenyl ) propane in a molar ratio of 83/17 (10.0 g).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001530317A JP4933012B2 (ja) | 1999-10-08 | 2000-10-05 | Cox−2抑制剤の製造方法 |
| CA2386807A CA2386807C (fr) | 1999-10-08 | 2000-10-05 | Procede de preparation d'inhibiteurs cox-2 |
| AT00967956T ATE304537T1 (de) | 1999-10-08 | 2000-10-05 | Verfahren zur herstellung von cox-2 inhibitoren |
| DE60022663T DE60022663T2 (de) | 1999-10-08 | 2000-10-05 | Verfahren zur herstellung von cox-2 inhibitoren |
| AU77944/00A AU773221B2 (en) | 1999-10-08 | 2000-10-05 | Method for producing cox-2 inhibitors |
| EP00967956A EP1218366B8 (fr) | 1999-10-08 | 2000-10-05 | Procede de preparation d'inhibiteurs cox-2 |
| US10/117,832 US6541646B2 (en) | 1999-10-08 | 2002-04-08 | Method of preparing COX-2 inhibitors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/12583 | 1999-10-08 | ||
| FR9912583A FR2799462B1 (fr) | 1999-10-08 | 1999-10-08 | Procede de preparation d'inhibiteurs cox-2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/117,832 Continuation US6541646B2 (en) | 1999-10-08 | 2002-04-08 | Method of preparing COX-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001027098A2 true WO2001027098A2 (fr) | 2001-04-19 |
| WO2001027098A3 WO2001027098A3 (fr) | 2001-08-30 |
Family
ID=9550723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2000/002770 Ceased WO2001027098A2 (fr) | 1999-10-08 | 2000-10-05 | Procede de preparation d'inhibiteurs cox-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6541646B2 (fr) |
| EP (1) | EP1218366B8 (fr) |
| JP (1) | JP4933012B2 (fr) |
| AT (1) | ATE304537T1 (fr) |
| AU (1) | AU773221B2 (fr) |
| CA (1) | CA2386807C (fr) |
| DE (1) | DE60022663T2 (fr) |
| DK (1) | DK1218366T3 (fr) |
| ES (1) | ES2249299T3 (fr) |
| FR (1) | FR2799462B1 (fr) |
| WO (1) | WO2001027098A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7531002B2 (en) * | 2004-04-16 | 2009-05-12 | Depuy Spine, Inc. | Intervertebral disc with monitoring and adjusting capabilities |
| EP1931327B1 (fr) * | 2005-08-19 | 2016-08-17 | Emisphere Technologies, Inc. | Composes cyclopropyles et compositions permettant de liberer des agents actifs |
| EP2833390A1 (fr) | 2013-08-02 | 2015-02-04 | Fei Company | Utilisation de lentille d'objectif électrostatique dans un microscope électronique |
| CN104803956A (zh) * | 2015-03-06 | 2015-07-29 | 江苏天和制药有限公司 | 非罗考昔的一种合成方法 |
| CN105859664A (zh) * | 2016-05-03 | 2016-08-17 | 中国药科大学 | 非罗考昔的一种制备方法 |
| CN107641108A (zh) * | 2017-11-12 | 2018-01-30 | 韦韬 | 一种非罗考昔的精制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA57002C2 (uk) * | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| HRP970289A2 (en) * | 1996-05-31 | 1998-04-30 | Merck & Co Inc | Process for preparing phenyl heterocycles useful as cox-2 inhibitors |
| DE69816047T2 (de) * | 1997-03-14 | 2004-04-22 | Merck Frosst Canada & Co, Kirkland | (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer |
| GB2330833A (en) * | 1997-10-29 | 1999-05-05 | Merck & Co Inc | PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS |
-
1999
- 1999-10-08 FR FR9912583A patent/FR2799462B1/fr not_active Expired - Lifetime
-
2000
- 2000-10-05 DE DE60022663T patent/DE60022663T2/de not_active Expired - Lifetime
- 2000-10-05 AT AT00967956T patent/ATE304537T1/de active
- 2000-10-05 CA CA2386807A patent/CA2386807C/fr not_active Expired - Lifetime
- 2000-10-05 EP EP00967956A patent/EP1218366B8/fr not_active Expired - Lifetime
- 2000-10-05 AU AU77944/00A patent/AU773221B2/en not_active Expired
- 2000-10-05 WO PCT/FR2000/002770 patent/WO2001027098A2/fr not_active Ceased
- 2000-10-05 DK DK00967956T patent/DK1218366T3/da active
- 2000-10-05 JP JP2001530317A patent/JP4933012B2/ja not_active Expired - Lifetime
- 2000-10-05 ES ES00967956T patent/ES2249299T3/es not_active Expired - Lifetime
-
2002
- 2002-04-08 US US10/117,832 patent/US6541646B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20030028036A1 (en) | 2003-02-06 |
| US6541646B2 (en) | 2003-04-01 |
| JP4933012B2 (ja) | 2012-05-16 |
| WO2001027098A3 (fr) | 2001-08-30 |
| DE60022663D1 (de) | 2005-10-20 |
| AU7794400A (en) | 2001-04-23 |
| AU773221B2 (en) | 2004-05-20 |
| EP1218366A2 (fr) | 2002-07-03 |
| EP1218366B1 (fr) | 2005-09-14 |
| FR2799462A1 (fr) | 2001-04-13 |
| EP1218366B8 (fr) | 2005-11-09 |
| ATE304537T1 (de) | 2005-09-15 |
| DE60022663T2 (de) | 2006-06-22 |
| DK1218366T3 (da) | 2006-01-23 |
| ES2249299T3 (es) | 2006-04-01 |
| CA2386807A1 (fr) | 2001-04-19 |
| FR2799462B1 (fr) | 2004-05-28 |
| CA2386807C (fr) | 2010-03-30 |
| JP2003511444A (ja) | 2003-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011107705A1 (fr) | Derives de cetobenzofurane ainsi que leur procede de synthese et le intermediaires | |
| EP2042497B1 (fr) | Procédé de synthèse du ranélate de strontium et de ses hydrates | |
| FR2566404A1 (fr) | Nouveaux derives de la 1,4-dihydropyridine, leurs sels, procede pour les preparer, et compositions pharmaceutiques les contenant | |
| EP1218366B8 (fr) | Procede de preparation d'inhibiteurs cox-2 | |
| EP0798308A1 (fr) | Esters phosphoriques d'alkyl ou d'acyl dianhydro-1,4:3,6-d-glucitol, procédé de préparation et utilisations | |
| CH464172A (fr) | Procédé de préparation d'acides carboxyliques -substitués | |
| EP0258160A2 (fr) | Dérivés de 2,3 dihydrofuranne leur procédé de préparation, leur utilisation comme intermédiaire pour la préparation de tétrahydrofuranne | |
| EP1205476A1 (fr) | Procédé de synthhèse de dérivés N-(mercaptoacyl)-amino-acides à partir d'acides acryliques alpha-substitués | |
| CA2640031A1 (fr) | Nouvelle methode de synthese de l,4-morpholine-2,5-diones | |
| EP0685473B1 (fr) | Composés benzohétérocycliques, en tant qu'antioxydants | |
| EP0069001A1 (fr) | Procédé de préparation de dérivés de la tétrahydro-5,6,7,7a 4H-thiéno (3,2-C) pyridinone-2 | |
| FR2752840A1 (fr) | Derives de benzothiophene, leur preparation et leur application en therapeutique | |
| FR2479213A1 (fr) | Procede de preparation d'acide pentenoique possedant une fonction aldehyde | |
| EP0350384B1 (fr) | Dérivés de sulfonyl indolizine, leur procédé de préparation et leur utilisation comme intermédiaires de synthèse | |
| JP2856814B2 (ja) | エポキシ誘導体およびその製造方法 | |
| EP0277052B1 (fr) | Dérivés de la 4,4-diméthyl tétrahydropyr-2-one, leur procédé de préparation et leur application à la synthèse de produits pyréthrinoides | |
| FR2580644A1 (fr) | Derives de l'acide ascorbique | |
| KR0163291B1 (ko) | 과산화수소수와 h2wo4를 이용한 2-술포닐티아졸 카르복실산 유도체의 제조방법 | |
| FR2555179A1 (fr) | Nouveaux (carbethoxy-2 furyl- ou benzofuryl-carboxamido-4 phenoxy)-1 amino-3 propanols-2 : leurs preparations et leurs applications en therapeutique | |
| WO2023156461A1 (fr) | Procede de preparation de composes comportant une structure 2,5-dihydrobenzoxepine par rearrangement photochimique | |
| CA2430302A1 (fr) | Procede de cyclisation pour la synthese de composes derives de pyrrolidine | |
| BE684910A (fr) | ||
| FR2903693A1 (fr) | Sulfinates et halogenures de sulfonyle aromatiques, et leur preparation. | |
| WO2001025206A1 (fr) | Procede de preparation de composes hydroximiques utiles en tant que fongicides | |
| FR2555169A2 (fr) | Nouveaux (carbethoxy-2 benzalkylamido-4 phenoxyl)-1 amino-3 propanols-2, leurs preparations et leurs utilisations en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2000967956 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 530317 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 77944/00 Country of ref document: AU Ref document number: 2386807 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10117832 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000967956 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 77944/00 Country of ref document: AU |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2000967956 Country of ref document: EP |




























































